Algoritmo sistematico di apprendimento automatico per il rilevamento rapido della trombosi (DVT-SMART)
Valutazione di una nuova strategia diagnostica per sospetto TVT costituito da D-Dimer D-Dimer, modello di previsione basato sull'intelligenza artificiale e ultrasuoni di compressione
The goal of this clinical trial is to compare the use of a machine learning-based algorithm and point-of-care D-dimer to laboratory D-dimer and compression ultrasound to exclude deep vein thrombosis in the under extremities in patients referred to a medical department suspected of having deep vein thrombosis. The main aim is to answer are if a machine learning algorithm and point of care D-dimer can exclude deep vein thrombosis in more patients than clinical assessment and D-dimer alone.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
All participants will follow the usual diagnostic algorithm used for patients with suspected DVT referred to Ostfold Hospital (all patients are examined by a physician, D-dimer is analyzed in all patients, ultrasound is performed by a radiologist in patients with positive D-dimer). In addition to usual care, POC D-dimer, POC ultrasound (performed by ED physicians), blood sampling for biobanking, and photographies of the under extremities will be performed. The machine learning model will be tested to see if the prediction is correct. In participants where ultrasound is performed, it will also be assessed whether the machine learning algorithm could have excluded the participant without the use of ultrasound. None of the additional procedures will have any impact on the patient diagnostics or treatment.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Waleed Ghanima, Professor
- Numero di telefono: 0047 69860000
- Email: waleed.ghanima@so-hf.no
Backup dei contatti dello studio
- Nome: Hans Joakim Myklebust-Hansen, Medical Doctor
- Numero di telefono: 0047 97501765
- Email: hans.joakim.hansen@so-hf.no
Luoghi di studio
-
-
-
Sarpsborg, Norvegia, 1714
- Reclutamento
- Østfold Hospital Trust
-
Contatto:
- Hans J Myklebust-Hansen, M.D.
- Numero di telefono: 004797501765
- Email: hansjoakim_mh@outlook.com
-
Sub-investigatore:
- Hans J Myklebust-Hansen, M.D.
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patients referred to the ED due to suspicion of DVT
- Age ≥ 18 years
- Able to give informed consent
Exclusion Criteria:
- Ongoing use of anticoagulation for more than 72 hours
- Previous participation in the study
- Life expectancy of less than three months.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Diagnostico
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: All participants
All participants will be treated the same way. |
POC D-dimer will be compared to laboratory D-dimer in hospital setting and used in a machine learning model Point of care (POC) ultrasound performed by ED physicians compared to ultrasound performed by radiologist. POC ultrasound 3 point examination performed by ED physician will be compared with POC ultrasound full leg examination performed by ED physician. The DSS will be compared to the usual strategy. It will also be estimated how many participants where DVT could have been excluded without ultrasound.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Safety of the new strategy (POC D-dimer, ML-based prediction model, POC CUS by emergency physician)
Lasso di tempo: From enrollment to the end of the primary assessment period (90 days)
|
Evaluate the safety of a new strategy consisting of POC D-dimer and an ML-based prediction model followed by CUS performed by emergency physicians by comparing the new strategy's safety with our standard care by measuring the proportion of patients in whom DVT is excluded according to the new strategy but was diagnosed with DVT by standard care or in whom DVT is diagnosed within the 90-day follow up. |
From enrollment to the end of the primary assessment period (90 days)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Evaluate the efficiency of the new strategy
Lasso di tempo: From enrollment to the end of the primary assessment period (90 days)
|
The proportion of patients in whom DVT can be ruled out by the ML-based prediction model with POC D-dimer compared to the efficiency of Wells score and laboratory D-dimer |
From enrollment to the end of the primary assessment period (90 days)
|
|
Validate the safety and efficiency of the ML-based prediction model
Lasso di tempo: From enrollment to the end of the primary assessment period (90 days)
|
Safety will be determined by the proportion of patients in whom DVT is excluded by the ML-model but diagnosed by standard care. Efficiency will be determined by the proportion of patients in whom DVT can be excluded by the ML-based model |
From enrollment to the end of the primary assessment period (90 days)
|
|
Evaluate concordance between CUS performed by emergency physicians and radiologists.
Lasso di tempo: From time of enrollment until time of ultrasound examination performed by radiologist, assessed up to 48 hours.
|
Determine the proportion of false negative and false positive diagnosis of DVT in emergency physician-performed ultrasound compared with ultrasound performed by radiologists. |
From time of enrollment until time of ultrasound examination performed by radiologist, assessed up to 48 hours.
|
|
Evaluate concordance between POC D-dimers in an ED setting and laboratory D-dimers.
Lasso di tempo: From enrollment to the completion of D-dimer analysis, assessed up to 24 hours.
|
Compare the two POC D-dimers with the STA-Liatest D-dimer and Siemens INNOVANCE by direct comparison of the true/false positive/negative results. |
From enrollment to the completion of D-dimer analysis, assessed up to 24 hours.
|
|
Evaluate the hypothetical time to be completed for the novel strategy compared to the standard strategy.
Lasso di tempo: From time of enrollment until time of discharge from the emergency department either discharged from the hospital or hospitalized, assessed up to 24 hours.
|
Estimating the total management time defined as time from ED registration to ED discharge in patients evaluated according to the new strategy compared to standard care. |
From time of enrollment until time of discharge from the emergency department either discharged from the hospital or hospitalized, assessed up to 24 hours.
|
|
Evaluate the safety of a limited ultrasound protocol (two-point and proximal) compared to full-leg CUS performed by emergency physicians and radiologists
Lasso di tempo: 90 days after enrollment.
|
Estimating the proportion of patients in whom DVT was ruled out by the limited ultrasound protocol but was diagnosed with DVT by the whole-leg ultrasound. |
90 days after enrollment.
|
Collaboratori e investigatori
Sponsor
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 682139
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
The plan to share IPD with other researchers are not yet decided because it has not yet been discussed.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .